Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
1,554
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Anna M. Tanasijevica Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Anna Revettea Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Heidi D. Klepinb Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
,
Amer Zeidanc Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USAView further author information
,
Danielle Townsleyd Oncology at MedImmune/AstraZeneca, Gaithersburg, MD, USAView further author information
,
Courtney D. DiNardoe Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Marie Sebertf Service de Hematologie Seniors, Hospital Saint Louis, Universit Paris 7, Paris, FranceView further author information
,
Amy E. DeZerng Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USAView further author information
,
Richard M. Stoneh Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Emily S. Magnavitaa Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Richard Chena Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Mikkael A. Sekeresi Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USAView further author information
&
Gregory A. Abela Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA;h Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 2900-2904 | Received 11 May 2020, Accepted 29 Jun 2020, Published online: 15 Jul 2020

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.